{"id":"W3174532254","doi":"10.1002/hon.51_2879","title":"NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Oncology; Phases of clinical research; Gastroenterology; Lymphoma; Surgery; CD30; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002161261,0.0009002369,0.001474513,0.0002473399,0.0002981147,0.001065536,0.0006894437,0.0007251184,0.002625272],"category_scores_gemma":[0.0009275958,0.0003658056,0.001714957,0.0003417142,0.0003621557,0.0005533501,0.000381928,0.0015828,0.0005576704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000695143,"about_ca_system_score_gemma":0.0008245254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008248236,"about_ca_topic_score_gemma":0.001910563,"domain_scores_codex":[0.9995812,0.0001955308,0.00002533422,0.00007070955,0.00006354317,0.00006374297],"domain_scores_gemma":[0.999418,0.00009974725,0.0001649911,0.00007222658,0.00004509414,0.0001999422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7865387,0.01933356,0.0355845,0.002134955,0.00642474,0.000422871,0.000295857,0.004124091,0.02165233,0.000227592,0.005806655,0.1174542],"study_design_scores_gemma":[0.522679,0.3148068,0.1366428,0.0002820621,0.006222775,0.001021057,0.00009949577,0.002565521,0.004297062,0.0003365882,0.01097447,0.00007228855],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894107,0.004917311,0.0003070901,0.0001679388,0.00007316036,0.001161363,0.002370473,0.00005076731,0.001541212],"genre_scores_gemma":[0.9859706,0.002901613,0.0007231346,0.0007266281,0.0001508107,0.001156447,0.006633383,0.0000214774,0.001715938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002625272,"threshold_uncertainty_score":0.01143003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112583095400109,"score_gpt":0.3361191188900827,"score_spread":0.2949932879360816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}